What Happened?
Palo Alto, CA-based Ocera-Therapeutics Promoted Michael Byrnes as Chief Financial Officer
About the Company
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease.
About the Person
Mr. Byrnes has served as Chief Financial Officer of Ocera Therapeutics, Inc. since December 2014. He joined Ocera in June 2014 as Vice President, Finance. Prior to joining Ocera, Mr. Byrnes served as Corporate Controller of Maxygen, Inc., MAXY since March 2010. From June 2007 to March 2010, Mr. Byrnes worked for NeurogesX, Inc., NGSX, in financial roles of increasing responsibility, most recently as Director of Finance. From December 2002 to June 2007, Mr. Byrnes served as Finance and Accounting Manager for Lipid Sciences Inc., LIPD. Mr. Byrnes`s experience also includes a variety of finance and accounting roles from 1996 to 2002 at ADAC Labs (a Philips Medical Systems company) and Bay View Capital Corporation. Mr. Byrnes received a B.S.C. in Finance from Santa Clara University and an M.B.A. from California State University, Hayward.
Info Source
Press Release
Short Profile